AARP reveals crucial new Medicare change

The Inflation Reduction Act-driven Medicare Part D negotiation program will impose lower, government‑negotiated prices on 10 brand drugs starting Jan. 1, 2026 and an additional 15 drugs beginning Jan. 1, 2027. CMS and AARP project roughly $1.5 billion in reduced beneficiary out‑of‑pocket costs in 2026, about $685 million in out‑of‑pocket relief tied to the 2027 cohort, and $8.5–$12 billion in annual Medicare savings from the negotiated agreements; the 15‑drug 2027 list accounts for roughly $40.7 billion in Part D spending for ~5.3 million beneficiaries. Hedge funds should re‑rate exposure to manufacturers of the named drugs (e.g., makers of Ozempic/Wegovy, Eliquis, Stelara, Jardiance, Xarelto) for potential revenue downside and monitor regulatory/political developments as industry pushback continues.

Analysis

Market structure: Medicare negotiation is an explicit transfer of pricing power away from large branded drugmakers toward payers and beneficiaries, with immediate winners being Medicare Advantage insurers and beneficiaries and losers being manufacturers with concentrated Part D revenue (e.g., names exposed to Januvia, Eliquis, Ozempic). Expect 5–25% U.S. price hits on negotiated molecules depending on CMS terms, raising equity volatility for impacted tickers while leaving global demand largely intact so dollar revenue declines will be partial not total.

Risk assessment: Tail risks include successful legal injunctions delaying implementation (near-term) or drugmakers reacting by shifting volume off-part D or increasing non-Medicare prices (medium-term), either of which could reverse market moves. Time horizon: days—event-driven volatility around CMS/manufacturer filings; weeks–months—pricing/contract adjustments and Q4 guidance; years—sustained margin pressure if cuts applied broadly (CMS projects $8.5–12B/yr savings as a reference magnitude).

Trade implications: Tactical play is to buy downside protection on concentrated pharma (6–12m put spreads) and rotate into Medicare Advantage/insurer equity and selective generics/biosimilars suppliers; pair trades (long UNH, short MRK/ABBV) capture relative benefit from lower Part D spend. Use options to size convexity: buy 6–12 month put spreads on high-exposure pharmas and buy 9–12 month call spreads on UNH/managed-care names; initiate hedges now and scale into positions as 2026/2027 implementation milestones and company guidances arrive.

Key Decisions for Investors

• Establish a 1.5% portfolio position: buy 12-month put spread on NVO (buy 1 15% OTM put, sell 1 30% OTM put) sized to cap max loss to ~0.4% portfolio to hedge downside from Ozempic/Wegovy Medicare price pressure expected 2027.
• Establish a 2–3% portfolio long in UnitedHealth (UNH) with a 6–12 month horizon; target +12–18% upside if MA margin tailwind materializes and trim to take profit at +15% or on signs MA margins deteriorate in quarterly guidance.
• Initiate 1% portfolio 6–12 month put spreads on MRK and 1% on ABBV (same structure: buy 12-month 10–15% OTM put, sell deeper OTM) to capture concentrated Part D exposure risk; reduce position size by 50% if either company discloses >10% revenue mitigation plans within 60 days.
• Within 30 days, trim pharma equity exposure by 20% for any holding where negotiated-drug sales exceed 5% of trailing revenue (apply to holdings like MRK, ABBV, NVO as relevant) and redeploy proceeds into MA insurers (UNH) and short-duration cash equivalents; if CMS litigation enjoins negotiations within 90 days, unwind >75% of short/puts and reallocate to cyclicals.